摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

PIM447 | 1210608-43-7

中文名称
——
中文别名
——
英文名称
PIM447
英文别名
N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide;N-{4-[(1r,3s,5s)-3-Amino-5-Methylcyclohexyl]pyridin-3-Yl}-6-(2,6-Difluorophenyl)-5-Fluoropyridine-2-Carboxamide;N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide
PIM447化学式
CAS
1210608-43-7
化学式
C24H23F3N4O
mdl
——
分子量
440.468
InChiKey
VRQXRVAKPDCRCI-ZNMIVQPWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    32
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    80.9
  • 氢给体数:
    2
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    [(1S,3R,5S)-3-(3-氨基吡啶-4-基)-5-甲基环己基]氨基甲酸叔丁酯 在 盐酸N-羟基-7-氮杂苯并三氮唑 、 sodium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 1,4-二氧六环乙酸乙酯N,N-二甲基甲酰胺 为溶剂, 反应 29.0h, 生成 PIM447
    参考文献:
    名称:
    Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies
    摘要:
    Pan proviral insertion site of Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitors have recently begun to be tested in humans to assess whether pan PIM kinase inhibition may provide benefit to cancer patients. Herein, the synthesis, in vitro activity, in vivo activity in an acute myeloid leukemia xenograft model, and preclinical profile of the potent and selective pan PIM kinase inhibitor compound 8 (PIM447) are described. Starting from the reported aminopiperidyl pan PIM kinase inhibitor compound 3, a strategy to improve the microsomal stability was pursued resulting in the identification of potent aminocyclohexyl pan PIM inhibitors with high metabolic stability. From this aminocyclohexyl series, compound 8 entered the clinic in 2012 in multiple myeloma patients and is currently in several phase 1 trials of cancer patients with hematological malignancies.
    DOI:
    10.1021/acs.jmedchem.5b01275
点击查看最新优质反应信息

文献信息

  • Kinase inhibitors and methods of their use
    申请人:BURGER Matthew T.
    公开号:US20100056576A1
    公开(公告)日:2010-03-04
    New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    提供了一种新的化合物、组合物和抑制与人类或动物宿主肿瘤发生相关的莫洛尼激酶(PIM激酶)活性的方法。在某些实施例中,该化合物和组合物能有效抑制至少一种PIM激酶的活性。这些新的化合物和组合物可以单独使用,也可以与至少一种其他试剂联合使用,用于治疗由丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的疾病,如癌症。
  • LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF
    申请人:ADURO BIOTECH, INC.
    公开号:US20190185511A1
    公开(公告)日:2019-06-20
    The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2′, 4′ locked nucleic acids within the cyclic dinucleotide.
    本发明提供了高活性的锁定核酸环二核苷酸(LNA-CDN)免疫刺激剂,通过细胞质受体STING(干扰素基因刺激剂)激活DCs。具体而言,本发明的LNA-CDNs以一种组合物的形式提供,该组合物包括一种或多种诱导人类STING依赖型I型干扰素产生的环二核苷酸,其中组合物中的环二核苷酸至少有一个2′, 4′锁定核酸。
  • Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof
    申请人:ADURO BIOTECH, INC.
    公开号:US10975114B2
    公开(公告)日:2021-04-13
    The present invention provides the cyclic dinucleotide compound 2′2′-RR-(3′F-A)(3′F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.
    本发明提供了环二核苷酸化合物2′2′-RR-(3′F-A)(3′F-A),作为一种高活性的免疫刺激剂,通过细胞质受体STING(干扰素基因刺激剂)激活DCs,以及其组合物和用途。
  • ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE
    申请人:Celgene Corporation
    公开号:US20200215060A1
    公开(公告)日:2020-07-09
    Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing multiple myeloma. The second active agent is one or more of a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an MEK inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BRD4 inhibitor, a PLK 1 inhibitor, an NEK2 inhibitor, an AURKB inhibitor, a BIRC5 inhibitor, a BET inhibitor, or a DNA methyltransferase inhibitor.
    本文提供了使用4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苯甲腈,或其对映体、对映体混合物、互变异构体或其药学上可接受的盐,与第二活性剂结合用于治疗、预防或管理多发性骨髓瘤的方法。第二活性剂是BTK抑制剂、mTOR抑制剂、PIM抑制剂、IGF-1R抑制剂、MEK抑制剂、XPO1抑制剂、DOT1L抑制剂、EZH2抑制剂、JAK2抑制剂、BRD4抑制剂、PLK1抑制剂、NEK2抑制剂、AURKB抑制剂、BIRC5抑制剂、BET抑制剂或DNA甲基转移酶抑制剂中的一个或多个。
  • [EN] COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" -DEPENDENT SIGNALLING<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'ACTIVATION DE LA SIGNALISATION DÉPENDANTE DE « STIMULATEUR DE GÈNES D'INTERFÉRON »
    申请人:ADURO BIOTECH INC
    公开号:WO2016145102A1
    公开(公告)日:2016-09-15
    The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinuclotides present in the composition are 2'-fluoro substituted, bis-3',5'CDNs, and most preferably one or more 2',2"-diF-Rp,Rp, bis-3',5'CDNs.
    本发明提供了高活性的环二核苷酸(CDN)免疫刺激剂,通过一种最近发现的细胞质受体STING(干扰素基因刺激因子)激活DCs。具体而言,本发明的CDN以一种组合物的形式提供,其中包括一种或多种环嘌呤二核苷酸,诱导人类STING依赖型I干扰素的产生,所述组合物中的环嘌呤二核苷酸为2'-氟取代的双3',5'CDNs,最好是一种或多种2',2"-二F-Rp,Rp,双3',5'CDNs。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-